一项针对胎儿RHD的无创产前游离DNA筛查试验在美国大型队列中的临床验证
该临床验证研究评估了基于下一代测序的商用游离DNA检测胎儿RHD状态的性能,纳入655例有血清学RhD结果的孕妇。检测在9周妊娠或以上可早期准确无创识别胎儿RHD基因型,灵敏度100%(95%CI 98.9-100%),特异度99.3%(95%CI 97.6-99.8%),有助于预防和管理RhD同种免疫。
要点
- 在655例RhD阴性孕妇中,游离DNA检测胎儿RHD的灵敏度为100%(95%CI 98.9-100%),特异度为99.3%(95%CI 97.6-99.8%)。
- 356例RhD阳性胎儿全部正确识别,297例RhD阴性胎儿中295例正确识别,并准确识别3例胎儿RHDΨ基因型。
- 该检测可在妊娠9周或以上早期、准确、无创地识别胎儿RHD基因型,可能有助于RhD同种免疫的预防和管理。
核心结论
- 在该大型美国RhD阴性患者队列中验证该检测,提供了在妊娠9周或以上早期、准确、无创识别胎儿RHD基因型的数据。
- 该检测有潜力协助患者和临床医生预防和管理RhD同种免疫。
研究设计与样本
- 这是一项临床验证研究,评估基于下一代测序的商用游离DNA检测胎儿RHD状态的性能。
- 纳入标准为:样本通过质量指标,且患者有先前报告的胎儿非整倍体游离DNA结果、母亲RhD阴性血清学、新生儿RhD血清学以及母亲RHD缺失或RHD-CE-D杂合基因型。
- 排除双卵双胎妊娠。
- 采用前瞻性游离DNA下一代测序分析评估母亲和胎儿RHD基因型,分析时研究者对胎儿RhD状态设盲。
- 队列由655例有RhD抗原血清学结果的孕妇组成。
主要发现
- 患者人口学特征包括RhD阴性美国人群中种族和民族的代表性分布:74.0%白人、13.7%西班牙裔、7.0%黑人、2.1%亚裔。
- 两例未报告游离DNA胎儿RHD结果。
- 无假阴性病例;356例胎儿中356例被正确识别为胎儿RhD阳性(灵敏度100%,95%CI 98.9-100%)。
- 297例RhD阴性胎儿中295例被正确识别为RhD阴性(特异度99.3%,95%CI 97.6-99.8%)。
- 在RhD表型阴性的胎儿中,游离DNA检测准确识别了3例携带胎儿RHD假基因(RHDΨ)基因型的胎儿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To present a large U.S. clinical validation of a next-generation sequencing-based, noninvasive prenatal cell-free DNA test for fetal RHD . METHODS: This clinical validation study assessed the performance of a commercially available, next-generation sequencing-based cell-free DNA test for fetal RHD status. Samples that passed quality metrics were included if the patient had a previously reported cell-free DNA result for fetal aneuploidy, maternal RhD-negative serology, newborn RhD serology, and maternal RHD deletion or RHD-CE-D hybrid(r's) genotype. Dizygotic twin pregnancies were excluded. Maternal and fetal RHD genotypes were evaluated with prospective cell-free DNA next-generation sequencing analysis. At the time of analysis, investigators were blinded to fetal RhD status. RESULTS: The cohort consisted of 655 pregnant patients with serologic results for RhD antigen. Patient demographics included a representative distribution of race and ethnicities in the RhD-negative U.S. population (74.0% White, 13.7% Hispanic, 7.0% Black, and 2.1% Asian). Cell-free DNA fetal RHD was not reported in two cases. There were zero false-negative cases; 356 of 356 fetuses were correctly identified as fetal RhD positive (sensitivity 100%, 95% CI, 98.9-100%). Of the 297 RhD-negative fetuses, 295 were correctly identified as RhD negative (specificity 99.3%, 95% CI, 97.6-99.8%). Of the fetuses with a negative RhD phenotype, the cell-free DNA test accurately identified three with the fetal RHD pseudogene ( RHDΨ) genotype. CONCLUSION: Validation of this test in this large U.S. cohort of RhD-negative patients provides data on early and accurate noninvasive prenatal identification of fetal RHD genotype at 9 weeks of gestation or more. This test has the potential to assist patients and clinicians in the prevention and management of RhD alloimmunization.
引用
- Gilstrop Thompson M, Xu W, Moore B, et al. Clinical Validation of a Prenatal Cell-Free DNA Screening Test for Fetal RHD in a Large U.S. Cohort. Obstet Gynecol. 2024. PMID: 39591628. doi:10.1097/AOG.0000000000005794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。